We are inspiring human belief in a healthier world
Our founding mission is to make highly quality medicines affordable and accessible to the world
30 years of Service in the pharmaceutical industry, backed by proven track record in R&D excellence
Our mission to enable access to affordable medicines and improve lives flow from the top
Expanding our presence to serve more people and create meaningful impact
Being acknowledged for our efforts motivates our entire team
Our expertise across APIs, global generics, biosimilars and custom pharmaceutical services is secured by a strong R&D backbone
We have steadily invested in a wide range of innovations to make our product portfolio diverse and differentiated in a competitive market
The path to serving patients better
World-class and differentiated portfolio in chronic therapy areas
Achieving a sustainable health equity
Fully integrated services across the value chain
Committed to transforming standards of care
Researching areas of unmet medical need
Our expertise rest on the pillars of our advanced R&D capabilities, world-class manufacturing facilities, our long legacy of trust and our partnerships
Research excellence for us means to invest in the future of health for the world
We invest in cutting edge research to develop new cures for challenging diseases
Built to world-class standards, our facilities enable us to produce high-quality and affordable medicines
Legacy of trust
Growing better, together
We are committed to making a positive impact by contributing to healthy communities and leading a responsible business
Aiming for a sustainable environment
A constant focus on sustainable environment with focus on health and safety
A steadfast commitment to enable communities
Hetero aims to report comprehensively and transparently for all stakeholders
Find range of resources including press releases, featured stories and information on social media channels
Access our latest press releases and resources for News and Media section
Discover the stories that enumerate the way we understand disease and develop medicines
Latest media releases and statements in the Hetero newsroom
Browse and download multimedia resources for use
Notices
Back
India, Hyderabad; 21 March, 2022: Hetero, a globally renowned vertically integrated pharmaceutical organization announced today that its biologics arm ‘Hetero Biopharma’ has received approval from the Central Drugs Standard Control Organisation (CDSCO) to manufacture for sale, Sputnik Light, with restricted emergency use in India. Hetero is the first biopharmaceutical company in India to receive manufacturing & marketing (M&M) approval for the product manufactured locally for the prevention of COVID-19 in adults aged over 18 years, administered in single dose of 0.5ml. All other currently approved vaccines in India require two doses of administration.
Sputnik Light is the first component (recombinant human adenovirus serotype number 26 (rAd26)) of Sputnik V – the world’s first registered vaccine against coronavirus disease, COVID19. In February 2022, the Drugs Controller General of India (DCGI) granted emergency use permission to Single-dose Sputnik Light COVID-19 vaccine in India.
“Clinical data of Sputnik Light (Component I of Sputnik V) had shown significantly high titers of antibodies against COVID-19, both glycoprotein specific and virus-neutralizing antibodies along with CD4 & IFN-γ levels. Sputnik Light has also shown its neutralizing activity against Omicron variant of SARS CoV-2 virus. Earlier Sputnik V clinical trials globally had shown significant protection against COVID-19 including other subtypes,” said Dr. Shubhadeep Sinha, Senior VP & Head - Clinical Development & Medical Affairs (CDMA) at Hetero.
About Hetero
Hetero is a globally renowned vertically integrated pharmaceutical organization engaged in research and development, manufacturing, and marketing of high-quality chemical and biologic medicines across diverse therapeutic areas. Backed by 27+ years of expertise in the pharmaceutical industry, Hetero’s strategic business areas spread across APIs, Global Generics, Biosimilars and Custom Pharmaceutical Services. The company is among the largest producers of Active Pharmaceutical Ingredients (APIs) in the world.
Hetero has 36 state-of-the-art manufacturing facilities strategically located worldwide, which has been approved by top pharma regulatory bodies of the world. Our portfolio includes 300+ products encompassing major therapeutic categories such as HIV/AIDS, Oncology, Cardiovascular, Neurology, Hepatitis, Nephrology etc. Hetero has a strong global presence in over 126 countries and focusses on making affordable medicines accessible to patients worldwide
Over the years, Hetero has established its strong leadership in ARVs and Antiviral therapies and caters to 40% of existing global demand for Anti-Retroviral (ARV) APIs and Finished Dosage Forms (FDFs) used in HIV/AIDS treatment. For more information on Hetero, please visit www.heteroworld.com.
For further details, please contact:
SreeRam Banda Head - Corporate Communications, Hetero Mobile: 97036 20166 Email: sreeram.b@heterodrugs.com